Protracted copy number alteration evolution in Barrett’s oesophagus leading to oesophageal cancer
Authors:
- Calum GabbuttCGCalum Gabbutt
- Angel Fernández-SanrománAFAngel Fernández-Sanromán
- Heather GrantHGHeather Grant
- Salvatore MiliteSMSalvatore Milite
- William Ch CrossWCWilliam Ch Cross
- Carlo C MaleyCarlo C Maley
- Andrea SottorivaASAndrea Sottoriva
- Giulio CaravagnaGCGiulio Caravagna
- Thomas G PaulsonTPThomas G Paulson
- Trevor A GrahamTGTrevor A Graham
Preprint
Abstract
Detection of copy number alterations (CNAs) in Barrett’s oesophagus (BO) predicts oesophageal adenocarcinoma (OAC) risk. When CNAs first occur is unknown. Here we show that CNAs typically form in BO many decades prior to first clinical detection of BO or cancer, and often during childhood. Using a novel molecular clock analysis, we analysed spatiotemporal longitudinal whole genome data from 80 individuals within BO surveillance. Chr 9p loss of heterozygosity (LOH) tended to be the first CNA event typically occurring at age 10-30 years. Genome doubling (GD) also typically originated multiple decades prior to cancer develop. Patients who progressed to OAC had an enrichment of CNAs late in life. CNA rate was more predictive of cancer risk than CNA burden. Analysis of OAC whole genomes confirmed the early-life origins of cancer-associated CNAs. The malignant transformation potential of BO may be set during the first decades of life, enabling early cancer interception.Keywords
Funding Information
- Wellcome Trust (202778/Z/16/Z)
- NIH (U54 CA217376)
- NIH (U2C CA233254)
- NIH (R21 CA257980)
- NIH (R01 CA140657)
- Instituto de Salud Carlos III (CEX2019-000891- S)
- Spanish Ministry of Science and Innovation (MCIN/AEI/10.13039/501100011033)
- La Caixa Foundation (100010434; LCF/BQ/DR21/11880009)
- European Molecular Biology Organization (EMBO Scientific Exchange Grant 10898)
- Congressionally Directed Medical Research Programs (BC132057)
This publication has 54 references indexed in Scilit:
- Aneuploidy in targeted endoscopic biopsies outperforms other tissue biomarkers in the prediction of histologic progression of Barrett's oesophagus: A multi-centre prospective cohort studyEBioMedicine, 2020
- ASGE guideline on screening and surveillance of Barrett’s esophagusGastrointestinal Endoscopy, 2019
- Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx RenalCell, 2018
- GATA6 expression in Barrett's oesophagus and oesophageal adenocarcinomaDigestive and Liver Disease, 2015
- Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohortThe Lancet Oncology, 2014
- Increasing incidence of Barrett’s oesophagus: a population-based studyEuropean Journal of Epidemiology, 2011
- Residual Embryonic Cells as Precursors of a Barrett's-like MetaplasiaCell, 2011
- p53 Mutations in Barrett's adenocarcinoma and high-grade dysplasiaGastroenterology, 1994
- Flow-cytometric and histological progression to malignancy in Barrett's esophagus: Prospective endoscopic surveillance of a cohortGastroenterology, 1992
- Barrett's esophagus in children: A consequence of chronic gastroesophageal refluxGastroenterology, 1984